Data from the Star trial of AngioDynamics‘ (NSDQ:ANGO) NanoKnife minimally invasive soft tissue ablation device showed it may prolong the lifespan of pancreatic cancer patients.
The study has been published in the Annals of Surgery, according to AngioDynamics.
The 200-patient trial examined individuals with locally advanced pancreatic cancer treated with irreversible electroporation with the NanoKnife. Of the patients, 50 were also treated with pancreatic resection in addition to IRE.
All patients in the study underwent induction chemotherapy, with 52% receiving chemo-radiation prior to IRE. Of the patients treated, 37% sustained median grade 2 complications and 3% experienced local recurrence, the company said. Median survival in both groups was 24.9 months.
Authors of the papers concluded that “IRE results in substantially prolonged survival of patients with LAPC compared with historical controls,” according to the Albany, N.Y.-based company.
The goal of the study was to evalute the effectiveness of IRE in combination with chemotherapy and/or chemoradiation to manage LAPC, the company said.
Last week, AngioDynamics said it enrolled the 1st patient in a new database analysis of patients treated with its AngioVac system. The Rapid database will evaluate patterns of use, safety and effectiveness data for patients treated with the AngioVac system to remove fresh, soft thrombi or emboli, the Albany, N.Y.-based company said.